Free CME

  • FREE

    Ocular surface disease (OSD): diagnostic, management, and clinical considerations in “dry eye”

    After completing Ocular surface disease (OSD): diagnostic, management, and clinical considerations in “dry eye” , you will be able to:

    • Discuss the causes, symptoms, and types of dry eye or ocular surface disease, emphasizing the pathophysiology that impacts treatment decisions
    • Describe the clinical implications of dry eye on contact lens or surgical success, and apply this knowledge in patient cases when discussing expectations with patients
    • Utilize patient history, ocular examination, and tear quantity tests to accurately diagnose ocular surface disease, with an emphasis on the importance of early diagnosis
    • Compare available and emerging treatments for ocular surface disease based on mechanisms of action and efficacy, with a focus on individualizing treatments to improve patient outcomes

    Target Audiences:

    Ophthalmologists, optometrists, physician assistants, nurse practitioners, nurses, and pharmacists who practice or are interested in ophthalmology; and any other healthcare professionals with an interest in or who clinically encounter patients with dry eye.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: June 16, 2017
    • Expiration of CME credit: June 16, 2020
  • FREE

    Congenital Thrombotic Thrombocytopenic Purpura (cTTP) (Upshaw-Schulman syndrome): Therapeutic Updates, Best Practices, and Emerging Therapies

    Thrombotic thrombocytopenic purpura (TTP) is a rare blood disorder that impacts three in a million adults per year, with congenital or hereditary TTP (cTTP, also known as Upshaw-Schulman syndrome) accounting for a third of the overall incidence. The incidence of TTP rises with increasing age and the mortality rate of untreated TTP may be as high as 90%.

    After reviewing Congenital Thrombotic Thrombocytopenic Purpura (cTTP) (Upshaw-Schulman syndrome): Therapeutic Updates, Best Practices, and Emerging Therapies physiicians will be able to:

    • Describe the pathophysiology of cTTP such that it might inform treatment mechanisms.
    • Identify diagnostic criteria and differential diagnoses for cTTP
    • Describe current treatment standards for the management of cTTP and apply them to patient cases
    • Describe new and emerging therapies for the treatment of cTTP and the existing literature support its use in practice
    • Evaluate the likelihood cTTP in a patient case and develop a treatment plan

    Target Audience: hematologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in hematology; and any other healthcare professionals with an interest in or who clinically encounter patients with cTTP.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: October 02, 2018
    • Expiration of CME credit: October 02, 2020
  • FREE

    Hemophilia B: Updates from 2018 American Society of Hematology Annual Meeting (ASH 2018)

    Hemophilia is a genetic disease caused by mutation of one of the genes for coagulation proteins leading to dangerous, uncontrolled bleeding. In hemophilia B, a mutation in the gene for factor IX (FIX) leads to an endogenous deficiency in the clotting factor

    After completing Hemophilia B: Updates from 2018 American Society of Hematology Annual Meeting (ASH 2018) physicians will better be able to:

    • Describe the gene therapy and its anticipated impact on hemophilia B therapy
    • List evidence-supported benefits of switching to extended half-life / dose-interval clotting factors and apply that knowledge to patient cases
    • Summarize the most impactful findings presented at ASH 2018 meeting relating to prophylactic and therapeutic agents to treat hemophilia B, and apply** them to patient cases
    • Describe how immune modulation therapy may be used to induce immune tolerance to Factor IX inhibitors

    Target Audience: hematologists; primary care physicians, physician assistants, nurse practitioners, nurses, and pharmacists who practice in hematology; and any other healthcare professionals with an interest in or who clinically encounter patients with hemophilia B.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 0.75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: March 05, 2019
    • Expiration of CME credit: March 05, 2021
  • FREE

    CME: Glaucoma: Updates from the AAO 2019 Annual Meeting

    Glaucoma, a heterogeneous disease leading to progressive damage to the optic nerve, causes irreversible vision loss and affects up to six million people in the U.S., and just as many worldwide have glaucoma-related bilateral blindness. The prevalence of glaucoma is increasing, and more than 100 million people across the globe will have glaucoma by 2040. Approximately half of all individuals with glaucoma are unaware of their condition due to the asymptomatic nature of the disease. Although the incidence of glaucoma-related blindness has decreased over the last 20 years thanks to effective management strategies, 13% to 40% of people with glaucoma still develop unilateral or bilateral blindness, typically at a rate of 1.1% per year.

    By the end of the session the participant will be able to:

    • Summarize the most impactful findings at the AAO 2019 meeting relating to glaucoma, including diagnostic testing, therapeutic success, and emerging therapies, and apply that knowledge to patients with different forms of glaucoma
    • Recall the results from the Horizon, LiGHT, and OHTS studies
    • List conditions that can masquerade as normal-tension glaucoma (NTG) and the role of systemic blood pressure in evaluation and management of NTG
    • Summarize the role of the following in glaucoma: hemoglobin video imaging, bimatoprost sustained-release implant, and the microshunt technology

    Target Audience:

    HCPs including: comprehensive ophthalmologists and retinal specialists; physician assistants and nurse practitioners who practice in ophthalmology; and any other HCPs with an interest in or who clinically encounter patients with glaucoma.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 04/10/2020
    • Expiration of CME credit: 04/10/2021
  • FREE

    CME: Management strategies for complications of chronic kidney disease (CKD): anemia and hyperphosphatemia

    Chronic Kidney Disease (CKD) affects about 15% of the general population in the United States according to data from the CDC’s National Health and Nutrition Examination Survey and causes a number of complications with anemia and hyperphosphatemia common among them. Anemia occurs in about 15% of patients and arises from a result of decreased production of erythropoietin (EPO) which signals bone marrow to produce red blood cells, whereas hyperphosphatemia occurs in the later stages of CKD because the kidney is the primary method by which the body maintains phosphate. This retention of phosphate leads to the development of CKD-Mineral Bone Disorder (CKD-MBD), with the literature suggesting that hyperphosphatemia occurs in a large portion of patients on dialysis based on usage of phosphate binders (PBs).

    By the end of the session the participant will be able to:

    • Describe common complications that patients with CKD experience
    • Describe management strategies for anemia and hypherphosphatemia of CKD and their impact
    • Determine appropriateness of therapies for anemia and hypherphosphatemia of CKD, given a patient case
    • Describe effective management strategies for monitoring anemia and hyperphosphatemia in patients with CKD, taking into account dialysis status

    Target Audience:

    The following healthcare professionals (HCPs): nephrologists and primary care physicians; physician assistants, nurse practitioners, and pharmacists who practice in nephrology; and any other HCPs with an interest in or who clinically encounter patients with CKD.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 3/5/2020
    • Expiration of CME credit: 3/5/2022
  • FREE

    CME: Hereditary angioedema (HAE): optimizing treatment strategies

    Hereditary angioedema (HAE) is a rare, debilitating, and potentially life-threatening disease due to C1-inhibitor (C1-INH) deficiency with an estimated frequency of 1 in 50,000 people. HAE is characterized by recurrent edema attacks and the cutaneous attacks can be disabling, with the skin, gastrointestinal tract, and upper airways are most commonly affected and with a persistent risk to the patient of acute events of laryngeal swelling that may prove fatal if not treated in a timely manner. Angioedema in general can be confused with cellulitis, Graves’ disease, blepharochalasis, eosinophilic fasciitis, or amyloidosis which can lead to delays in diagnosis, and inappropriate treatment poses the risk of adverse events, unnecessary surgical interventions, a higher burden of misery, and a potentially higher rate of morbidity and mortality.

    By the end of the session the participant will be able to:

    • Recall the pathophysiology of HAE such that it might inform treatment mechanisms
    • Recognize the risks associated with misdiagnosis of HAE
    • Evaluate a treatment plan for a patient with HAE designed to optimize safety and efficacy, suggesting modifications for improvement
    • Describe present and emerging drug therapies for management of HAE and apply them to patient cases taking into account the patient’s history or anticipated place in therapy

    Target Audience:

    Healthcare professionals who are: allergists, immunologists, and internists; physician assistants, nurse practitioners, nurses, and pharmacists specializing in immunology; and any other HCPs who have an interest in or otherwise clinically encounter patients with HAE.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 3/23/2020
    • Expiration of CME credit: 3/23/2022
  • FREE

    CME: Advanced prostate cancer: optimizing management strategies

    Prostate cancer is the most common form of malignancy among men in the United States.There are over 164,600 new cases and over 29,000 deaths from PC in the U.S. annually. Probable risk factors include age 65 and older, African American ancestry, family history, and mutations in the BRCA1, -2, MSH2, and HOXB13 genes, with possible risk factors including occupational exposure to cadmium, dietary factors, and higher concentrations of serum testosterone. About 95% of cases are adenocarcinoma, with neuroendocrine tumors, sarcomas, and transitional cell carcinomas comprising the balance of tumor types. Symptoms of advanced prostate cancer (aPC) include back pain, cord compression, lower extremity edema, pathologic fractures, anemia, and weight loss.

    By the end of the session the participant will be able to:

    • Recall the pathophysiology of aPC in a manner that informs treatment mechanisms
    • Describe differences in approach between hormone-sensitive and castration-resistant aPC
    • Identify the treatment modalities currently available for management of aPC and apply them to patient cases using evidence-based medicine
    • Describe emerging treatment options presently available for aPC, their mechanisms of action and safety, and anticipated place in therapy
    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 3/13/2020
    • Expiration of CME credit: 3/13/2021
  • FREE

    CME: Improving the treatment and management of schizophrenia: an overview of current and novel approaches

    Schizophrenia, by nature, presents manifold challenges to the HCP directing neuropsychiatric care. Not only do practical matters like medication adherence play a role in the success of therapy, but it behooves clinicians to also have a well-informed understanding of the symptomatology and treatment course of the disease. Atypical antipsychotics are the mainstay of initial pharmacotherapy, with oral agents being preferred first. However, they have sometimes been associated with poor patient adherence, which is associated with suboptimal clinical outcomes. In contrast, improving adherence may enhance quality of life and reduce the risk of hospitalization, thereby potentially lowering health resource utilization and its associated costs.

    By the end of the session the participant will be able to:

    • Describe the pathophysiology of schizophrenia and the role the neurotransmitters receptors play in it: D2, D3, 5-HT2A
    • Describe the benefits and risks of pharmacotherapy for schizophrenia and take them into account when formulating a treatment plan for different patients
    • Formulate a treatment plan for a variety of patients with schizophrenia, including those exhibiting only negative symptoms
    • Recommend therapy changes in patients who are unable to tolerate a prescribed treatment
    • Identify barriers to care in patients with schizophrenia and develop** strategies to abate them

    Target Audience:

    Healthcare professionals who are: psychiatrists and primary care physicians; nurse practitioners, physician assistants, nurses, and pharmacists who specialize in psychiatry; and those who otherwise commonly care for or clinically encounter patients who have schizophrenia.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 3/6/2020
    • Expiration of CME credit: 3/6/2022
  • FREE

    CME: Cold agglutinin disease (CAD): Updates from the American Society of Hematology (ASH) 2019 annual meeting

    Cold agglutinin disease (CAD) is a subtype of autoimmune hemolytic anemia (AIHA) and characterized by cold agglutinin (CA) autoantibodies that cause the erythrocytic hemolysis. Also known as primary or idiopathic CAD, it is distinguished further from cold agglutinin syndrome (CAS), which is a complication of known conditions such as malignancy, infection, or autoimmune disease. Little is known about the epidemiology of CAD; one small study estimated incidence of 1 per 1 million people and prevalence of 1 per 16 million people with females twice as likely males to develop the disease and a median age of onset of 67 years.

    By the end of the session the participant will be able to:

    • Describe the pathogenesis and symptomology of AIHA generally and CAD specifically
    • Describe how diagnosis of CAD is distinguished from other subtypes of AIHA and challenges to successful identification of patients
    • Describe present and emerging treatment options for CAD and monitoring parameters for effectiveness of treatment
    • Develop a safe and clinically effective treatment plan including non-pharmacologic and pharmacologic therapy for patients with CAD

    Target Audience:

    The following healthcare professionals (HCPs): hematologists, oncologists, immunologists; physician assistants, nurse practitioners, and pharmacists who practice in the aforementioned areas of specialty; and any other HCPs with an interest in or who clinically encounter patients with CAD.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 2/21/2020
    • Expiration of CME credit: 2/21/2021
  • FREE

    CME: Glaucoma: optimizing pharmacotherapeutic management strategies

    Glaucoma, a heterogeneous disease leading to progressive damage to the optic nerve, causes irreversible vision loss and affects up to six million people in the U.S., and just as many worldwide have glaucoma-related bilateral blindness. The prevalence of glaucoma is increasing, and more than 100 million people across the globe will have glaucoma by 2040. Approximately half of all individuals with glaucoma are unaware of their condition due to the asymptomatic nature of the disease. Although the incidence of glaucoma-related blindness has decreased over the last 20 years thanks to effective management strategies, 13% to 40% of people with glaucoma still develop unilateral or bilateral blindness, typically at a rate of 1.1% per year.

    By the end of the session the participant will be able to:

    • Individualize intraocular pressure targets based on known risk factors and patient-specific characteristics, and optimize assessment of intraocular pressure profiles to readily identify peaks and fluctuations
    • Identify first-line pharmacotherapies, laser therapies, and glaucoma implants for lowering intraocular pressure, and select appropriate monotherapies and combination therapies for patients
    • Discuss present and emerging pharmacotherapies currently in clinical development and their mechanisms of action, and apply those therapies to patient cases
    • Describe barriers to care in the treatment of patients with glaucoma and what clinicians may do to aide patients in circumventing them

    Target Audience:

    Healthcare professionals (HCPs) including: comprehensive ophthalmologists and retinal specialists; physician assistants and nurse practitioners who practice in ophthalmology; and any other HCPs with an interest in or who clinically encounter patients with glaucoma.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 2/17/2020
    • Expiration of CME credit: 2/17/2022